Review of histopathological and molecular prognostic features in colorectal cancer

Cancers

Volumn 3, Issue 2, 2011, Pages 2767-2810

  Marzouk, Ola ^a   Schofield, John ^a  

^a MAIDSTONE HOSPITAL   (United Kingdom)

Author keywords

Colorectal cancer; Histomorphological factors; Lymph nodes; Micrometastases; Molecular biomarkers; Predictive factors; Prognostic factors; Resection margins; Sentinel node sampling; TNM classification

Indexed keywords

B RAF KINASE; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; GRANZYME B; GUANYLATE CYCLASE; GUANYLATE CYCLASE C; IRINOTECAN; K RAS PROTEIN; MISMATCH REPAIR PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MLH1; PROTEIN MLH2; RAF PROTEIN; RAS PROTEIN; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIGEN DETECTION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER INVASION; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER STEM CELL; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD57+ T CELL; CD8+ T LYMPHOCYTE; CHROMOSOMAL INSTABILITY; CHROMOSOME 18Q; COLORECTAL CANCER; COLORECTAL CARCINOMA; CPG ISLAND; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; DISSECTION; DNA METHYLATION; EARLY CANCER; EXTRAMURAL CANCER DEPOSIT; GENE MUTATION; GENETIC SCREENING; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; HYPERTHERMIC THERAPY; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE; LYMPH NODE METASTASIS; LYMPH VESSEL; LYMPHADENECTOMY; LYMPHOCYTIC INFILTRATION; MEDULLARY CARCINOMA; METASTASIS; MICROMETASTASIS; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PELVIS LYMPHADENECTOMY; PERINEURIUM; PERITONEAL CARCINOMATOSIS; PERITONEUM TUMOR; PHENOTYPE; POLYP; POLYPECTOMY; PREOPERATIVE EVALUATION; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECTUM ABDOMINOPERINEAL RESECTION; RECTUM CANCER; RECTUM RESECTION; RECURRENCE RISK; REVIEW; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; SIGNET RING CARCINOMA; SUBMUCOSA; SURVIVAL RATE; T LYMPHOCYTE SUBPOPULATION; TUMOR BUDDING; TUMOR DIFFERENTIATION; TUMOR IMMUNITY; TUMOR VOLUME;

EID: 79959685872     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3022767     Document Type: Review

References (244)

1. Dukes, C. The classification of cancer of the rectum. J. Pathol. Bacteriol. 1932, 34, 323.
2. Moertel, C.G.; O'Fallon, J.R.; Go, V.L.; O'Connell, M.J.; Thynne, G.S. The preoperative carcinoembryonic antigen test in the diagnosis, staging; and prognosis of colorectal cancer. Cancer 1986, 58, 603-610.
3. Wang, J.Y.; Tang, R.; Chiang, J.M. Value of carcinoembryonic antigen in the management of colorectal cancer. Dis. Colon Rectum 1994, 37, 272-277.
4. Park, I.J.; Choi, G.S.; Lim, K.H.; Kang, B.M.; Jun, S.H. Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: Clinical significance of the preoperative level. Ann. Surg. Oncol. 2009, 16, 3087-3093.
5. Kim, J.Y.; Kim, N.K.; Sohn, S.K.; Kim, Y.W.; Kim, K.J.; Hur, H.; Min, B.S.; Cho, C.H. Prognostic value of postoperative CEA clearance in rectal cancer patients with high preoperative CEA levels. Ann. Surg. Oncol. 2009, 16, 2771-2778.
6. Slentz, K.; Senagore, A.; Hibbert, J.; Mazier, W.P.; Talbott, T.M. Can preoperative and postoperative CEA predict survival after colon cancer resection? Am. Surg. 1994, 60, 528-531.
7. Takagawa, R.; Fujii, S.; Ohta, M.; Nagano, Y.; Kunisaki, C.; Yamagishi, S.; Osada, S.; Ichikawa, Y.; Shimada, H. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer. Ann. Surg. Oncol. 2008, 15, 3433-3439.
8. Wolmark, N.; Fisher, B.; Wieand, H.S.; Henry, R.S.; Lerner, H.; Legault-Poisson, S.; Deckers, P.J.; Dimitrov, N.; Gordon, P.H.; Jochimsen, P., et al. The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer. Results from NSABP (National Surgical Adjuvant Breast and Bowel Project) clinical trials. Ann. Surg. 1984, 199, 375-382.
9. Harrison, L.E.; Guillem, J.G.; Paty, P.; Cohen, A.M. Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: A multivariate analysis of 572 patients. J. Am. Coll. Surg. 1997, 185, 55-59.
10. Dukes, C.E. The surgical pathology of rectal cancer: President's address. Proc. R. Soc. Med. 1944, 37, 131-144.
11. Turnbull, R.B., Jr.; Kyle, K.; Watson, F.R.; Spratt, J. Cancer of the colon: The influence of the no-touch isolation technic on survival rates. Ann. Surg. 1967, 166, 420-427.
12. Gunderson, L.L.; Sosin, H. Areas of failure found at reoperation (second or symptomatic look) following "curative surgery" for adenocarcinoma of the rectum. Clinicopathologic correlation and implications for adjuvant therapy. Cancer 1974, 34, 1278-1292.
13. Astler, V.B.; Coller F.A. The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann. Surg. 1954, 139, 846-852.
14. Sobin, L.H.; Godspodarowicz, M.K.; Wittekind, C. UICC TNM Classification of Malignant Tumours, 7th ed.; Wiley-Blackwell: Chichester, UK, 2009; pp. 100-105.
15. Jass J.R.; Love S.B.; Northover, J.M. A new prognostic classification of rectal cancer. Lancet 1987, 1, 1303-1306.
16. Jass, J.R.; Morson, B.C. Reporting colorectal cancer. J. Clin. Pathol. 1987, 40, 1016-1023.
17. Ueno, H.; Price, A.B.; Wilkinson, K.H.; Jass, J.R.; Mochizuki, H.; Talbot, I.C. A new prognostic staging system for rectal cancer. Ann. Surg. 2004, 240, 832-839.
18. Puppa, G.; Sonzogni, A.; Colombari, R.; Pelosi, G. TNM staging system of colorectal carcinoma, a critical appraisal of challenging issues. Arch. Pathol. Lab. Med. 2010, 134, 837-852.
19. Gunderson, L.L.; Jessup, J.M.; Sargent, D.J.; Greene, F.L.; Stewart, A.K. Revised TN categorization for colon cancer based on national survival outcomes data. J. Clin. Oncol. 2010, 28, 264-271.
20. UICC ⌊ International Union Against Cancer Website. Available online: http://old.uicc.org/index.php?option=com_content&task=view&id=14297&Itemid=429/ (accessed 20 June 2011).
21. Quirke, P.; Williams, G.T.; Ectors, N.; Ensari, A.; Piard, F.; Nagtegaal, I. The future of the TNM staging system in colorectal cancer: Time for a debate? Lancet Oncol. 2007, 8, 651-657.
22. Greene, F.L. Current TNM staging of colorectal cancer. Lancet Oncol. 2007, 8, 572-573.
23. Wittekind, C.; Henson, D.E.; Hutter, R.V.; Sobin, L.H. TNM Supplement: A Commentary on Uniform Use, 3rd ed.; John Wiley & Sons: Hoboken, New Jersey, NJ, USA, 2003.
24. Priolli, D.G.; Cardinalli, I.A.; Pereira, J.A.; Alfredo, C.H.; Margarido, N.F.; Real Martinez, C.A. Metastatic lymph node ratio as an independent prognostic variable in colorectal cancer: Study of 113 patients. Tech. Coloproctol. 2009, 13, 113-121.
25. Choi, H.; Law, W.; Poon, J. The optimal number of lymph nodes examined in stage II colorectal cancer and its impact of on outcomes. BMC Cancer 2010, 10, 267.
26. Shen, S.S.; Haupt, B.X.; Ro, J.Y.; Zhu, J.; Bailey, H.R.; Schwartz, M.R. Number of lymph nodes examined and associated clinicopathologic factors in colorectal carcinoma. Arch. Pathol. Lab. Med. 2009, 133, 781-786.
27. Elferink, M.A.; Siesling, S.; Visser, O.; Rutten, H.J.; van Krieken, J.H.; Tollenaar, R.A.; Lemmens, V.E. Large variation between hospitals and pathology laboratories in lymph node evaluation in colon cancer and its impact on survival, a nationwide population-based study in the Netherlands. Ann. Oncol. 2011, 22, 110-117.
28. Haince, J-F.; Houde, M.; Beaudry, G.; L'Esperance, S.; Garon, G.; Desaulniers, M.; Hafer, L.J.; Heald, J.I.; Lyle, S.; Grossman, S.R.; et al. Comparison of histopathology and RT-qPCR amplification of guanylyl cyclase C for detection of colon cancer metastases in lymph nodes. J. Clin. Pathol. 2010, 63, 530-537.
29. Desolneux, G.; Pascal Burtin, P.; Lermite, E.; Bergamaschi, R.; Hamy, A.; Arnaud, J.P. Prognostic factors in node-negative colorectal cancer: A retrospective study from a prospective database. Int. J. Colorectal Dis. 2010, 25, 829-834.
30. Huh, J.W.; Kim, H.R.; Kim, Y.J. Lymphovascular or perineural invasion may predict lymph node metastasis in patients with T1 and T2 colorectal cancer. J. Gastrointest. Surg. 2010, 14, 1074-1080.
31. Tominaga, K.; Nakanishi, Y.; Nimura, S.; Yoshimura, K.; Sakai, Y.; Shimoda, T. Predictive histopathologic factors for lymph node metastasis in patients with nonpedunculated submucosal invasive colorectal carcinoma. Dis. Colon Rectum 2005, 48, 92-100.
32. Haggitt, R.C.; Glotzbach, R.E.; Soffer E.E.; Wruble, L.D. Prognostic factors in colorectal carcinomas arising in adenomas: Implications for lesions removed by endoscopic polypectomy. Gastroenterology 1985, 89, 328-336.
33. Suzuki, T.; Sadahiro, S.; Mukoyama, S.; Ishikawa, K.; Yasuda, S.; Tajima, T.; Makuuchi, H.; Murayama, C. Risk of lymph node and distant metastases in patients with early invasive colorectal cancer classified as Haggitt's level 4 invasion: Image analysis of submucosal layer invasion. Dis. Colon Rectum 2003, 46, 203-208.
34. Tateishi, Y.; Nakanishi, Y.; Taniguchi, H.; Shimoda, T.; Umemura, S. Pathological prognostic factors predicting lymph node metastasis in submucosal invasive (T1) colorectal carcinoma. Mod. Pathol. 2010, 23, 1068-1072.
35. Sohn, D.K.; Chang, H.J.; Park, J.W.; Choi, D.H.; Han, K.S.; Hong, C.W.; Jung, K.H.; Kim, D.Y.; Lim, S.; Choi, H.S., et al. Histopathological risk factors for lymph node metastasis in submucosal invasive colorectal carcinoma of pedunculated or semipedunculated type. J. Clin. Pathol. 2007, 60, 912-915.
36. Nascimbeni, R.; Burgart, L.J.; Nivatvongs, S.; Larson, D.R. Risk of lymph node metastasis in T1 carcinoma of the colon and rectum. Dis. Colon Rectum 2002, 45, 200-206.
37. Saha, S.; Monson, K.M.; Bilchik, A.; Beutler, T.; Dan, A.G.; Schochet, E.; Wiese, D.; Kaushal, S.; Ganatra, B.; Desai, D. Comparative analysis of nodal upstaging between colon and rectal cancers by sentinel lymph node mapping, a prospective trial. Dis. Colon Rectum 2004, 47, 1767-1772.
38. Joosten, J.J.; Strobbe, L.J.; Wauters, C.A.; Pruszczynski, M.; Wobbes, T.; Ruers, T.J. Intraoperative lymphatic mapping and the sentinel node concept in colorectal carcinoma. Br. J. Surg. 1999, 86, 482-486.
39. Cahill, R.A.; Leroy, J.; Marescaux, J. Could lymphatic mapping and sentinel node biopsy provide oncological providence for local resectional techniques for colon cancer? A review of the literature. BMC Surg. 2008, 24, 8-17.
40. Pocard, M.; Van den Eynde, M.; Goere, D.; Boige, V.; Malka, D. Sentinel lymph node sampling and analysis in colon cancer: What is the question? J. Clin. Oncol. 2006, 24, 3712-3713.
41. Bilchik, A.J.; Saha, S.; Wiese, D.; Stonecypher, J.A.; Wood, T.F.; Sostrin, S.; Turner, R.R.; Wang, H.J.; Morton, D.L.; Hoon, D.S. Molecular staging of early colon cancer on the basis of sentinel node analysis: A multicenter phase II trial. J. Clin. Oncol. 2001, 15, 1128-1136.
42. Bertoglio, S.; Sandrucci, S.; Percivale, P.; Goss, M.; Gipponi, M.; Moresco, L.; Mussa, B.; Mussa, A. Prognostic value of sentinel lymph node biopsy in the pathologic staging of colorectal cancer patients. J. Surg. Oncol. 2004, 85, 166-170.
43. Kelder, W.; Braat, A.E.; Karrenbeld, A.; Grond, J.A.K.; De Vries, J.E.; Oosterhuis, J.W.A.; Baas, P.C.; Plukker, J.T.M. The sentinel node procedure in colon carcinoma: A multi-centre study in The Netherlands. Int. J. Colorectal Dis. 2007, 22, 1509-1514.
44. Liberale, G.; Lasser, P.; Sabourin, J.C.; Malka, D.; Duvillard, P.; Elias, D.; Boige, V.; Goéré, D.; Ducreux, M.; Pocard, M. Sentinel lymph nodes of colorectal carcinoma, reappraisal of 123 cases. Gastroenterol. Clin. Biol. 2007, 31, 281-285.
45. Lasser, P.; Côté, J.F.; Sabourin, J.C.; Boige, V.; Elias, D.; Duvillard, P.; Pocard, M. Intéret de l'analyse du ganglion sentinelle pour les cancers coliques: Etude de faisabilité [Is sentinel lymph node mapping relevant for colon cancer? A feasibility study]. Ann. Chir. 2003, 128, 433-437.
46. Baton, O.; Lasser, P.; Sabourin, J.C.; Boige, V.; Duvillard, P.; Elias, D.; Malka, D.; Ducreux, M.; Pocard, M. Ex vivo sentinel lymph node study for rectal adenocarcinoma: Preliminary study. World J. Surg. 2005, 29, 1166-1170; discussion 1171.
47. Bertagnolli, M.; Miedema, B.; Redston, M.; Dowell, J.; Niedzwiecki, D.; Fleshman, J.; Bem, J.; Mayer, R.; Zinner, M.; Compton, C. Sentinel node staging of resectable colon cancer: Results of a multicenter study. Ann. Surg. 2004, 240, 624-628; discussion 628-630.
48. Redston, M.; Compton, C.C.; Miedema, B.W.; Niedzwiecki, D.; Dowell, JM.; Jewell, SD.; Fleshman, J.M.; Bem, J.; Mayer, R.J.; Bertagnolli, M.M. Leukemia Group B Trial 80001. Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: Results of Cancer and Leukemia Group B Trial 80001. J. Clin. Oncol. 2006, 24, 878-883.
49. Quadros, C.A.; Lopes, A.; Araujo, I.; Fregnani, J.H.; Fahel, F. Upstaging benefits and accuracy of sentinel lymph node mapping in colorectal adenocarcinoma nodal staging. J. Surg. Oncol. 2008, 98, 324-330.
50. Lim, S.J.; Feig, B.W.; Wang, H.; Hunt, K.K.; Rodriguez-Bigas, M.A.; Skibber, J.M.; Ellis, V.; Cleary, K.; Chang, G.J. Sentinel lymph node evaluation does not improve staging accuracy in colon cancer. Ann. Surg. Oncol. 2008, 15, 46-51.
51. Fitzgerald, T.L.; Khalifa, M.A.; Al Zahrani, M.; Law, C.H.; Smith, A.J. Ex vivo sentinel lymph node biopsy in colorectal cancer: A feasibility study. J. Surg. Oncol. 2002, 80, 27-32, discussion 33.
52. Smith, J.; Hwang, H.; Wiseman, K.W.; Filipenko, D.; Phang, P.T. Ex vivo sentinel lymph node mapping in colon cancer: Improving the accuracy of pathologic staging? Am. J. Surg. 2006, 191, 665-668.
53. Bembenek, A.E.; Rosenberg, R.; Wagle, E.; Gretschel, S.; Sendler, A.; Siewert, J.R.; Nährig, J.; Witzigmann, H.; Hauss, J.; Knorr, C., et al. Sentinel lymph node biopsy in colon cancer: A prospective multicenter trial. Ann. Surg. 2007, 245, 858-863.
54. Sticca, R.P. Is there clinical value to sentinel lymph node sampling in colon cancer? J. Clin. Oncol. 2006, 24, 841-842.
55. Scabini, S. Sentinel node biopsy in colorectal cancer: Must we believe it? World J. Gastrointest. Surg. 2010, 2, 6-8.
56. Takahashi, T.; Ueno, M.; Azekura, K.; Ohta, H. Lateral node dissection and total mesorectal excision for rectal cancer. Dis. Colon Rectum 2000, 43 (Suppl. 10), S59-S68.
57. Ueno, H.; Mochizuki, H.; Hashiguchi, Y.; Hase, K. Prognostic determinant of patients with lateral nodal involvement by rectal cancer. Ann. Surg. 2001, 234, 190-197.
58. Hida, J.; Yasutomi, M.; Fujimoto, K.; Maruyama, T.; Okuno, K.; Shindo, K. Does lateral lymph node dissection improve survival in rectal carcinoma? Examination of node metastases by the clearing method. J. Am. Coll. Surg. 1997, 184, 475-480.
59. Wu, Z-Y.; Wan, J.; Li, J-H.; Zhao, G.; Yao, Y.; Du, J-L.; Liu, Q-F.; Peng, L.; Wang, Z-D.; Huang, Z-M., et al. Prognostic value of lateral lymph node metastasis for advanced low rectal cancer. World J. Gastroenterol. 2007, 13, 6048-6052.
60. Wu, Z.Y.; Wan, J.; Yao, Y.; Zhao, G.; Du, J.L.; Yang, J. Clinic study of lateral lymph node metastasis in advanced lower rectal cancer. Zhonghua Wai Ke Za Zhi 2008, 46, 190-192.
61. Pan, Y.S.; Wan, Y.L.; Liu, Y.C.; Wang, X.; Wu, T. Lateral pelvic lymph node metastasis is an important prognostic factor for low rectal cancer. Zhonghua Wai Ke Za Zhi 2009, 47, 984-987.
62. Min, B.S.; Kim, J.S.; Kim, N.K.; Lim, J-S.; Lee, K.Y.; Cho, C.H.; Sohn, S.K. Extended lymph node dissection for rectal cancer with radiologically diagnosed extramesenteric lymph node metastasis. Ann. Surg. Oncol. 2009, 16, 3271-3278.
63. Koch, M.; Kienle, P.; Antolovic, D.; Büchler, M.W.; Weitz, J. Is the lateral lymph node compartment relevant? Rec. Res. Cancer Res. 2005, 165, 40-45.
64. Moriya, Y.; Hojo, K.; Sawada, T.; Koyama, Y. Significance of lateral node dissection for advanced rectal carcinoma at or below the peritoneal reflection. Dis. Colon Rectum 1989, 32, 307-315.
65. Ueno, H.; Mochizuki, H.; Hashiguchi, Y.; Ishiguro, M.; Miyoshi, M.; Kajiwara, Y.; Sato, T.; Shimazaki, H.; Hase, K. Potential prognostic benefit of lateral pelvic node dissection for rectal cancer located below the peritoneal reflection. Ann. Surg. 2007, 245, 80-87.
66. Kell, M.R.; Winter, D.C.; O'Sullivan, G.C.; Shanahan, F.; Redmond, H.P. Biological behaviour and clinical implications of micrometastases. Br. J. Surg. 2000, 87, 1629-1639.
67. Iddings, D.; Ahmad, A.; Elshoff, D.; Bilchik, A. The ptognostic effect of micrometastases in previously staged lymph node negative (N0) colorectal carcinoma: A meta-analysis. Ann. Surg. Oncol. 2006, 13, 1386-1392.
68. Jayne, D.G.; Fook, S.; Loi, C.; Seow-Choen, F. Peritoneal carcinomatosis from colorectal cancer. Br. J. Surg. 2002, 89. 1545.
69. Sadahiro, S.; Suzuki, T.; Maeda, Y.; Tanaka, A.; Makuuchi, H.; Kamijo, A.; Haruki, Y.; Murayama, C. Prognostic factors in patients with synchronous peritoneal carcinomatosis (PC) caused by a primary cancer of the colon. J. Gastrointest. Surg. 2009, 13, 1593-1598.
70. Rosen, S.A.; Buell, J.F.; Yoshida, A.; Kazsuba, S.; Hurst, R.; Michelassi, F.; Millis, J.M.; Posner, M.C. Initial presentation with stage IV colorectal cancer: How aggressive should we be? Arch. Surg. 2000, 135, 530-534.
71. Teo, M. Peritoneal-based malignancies and their treatment. Ann. Acad. Med. Singapore 2010, 39, 54-57.
72. Verwaal, V.J.; van Ruth, S.; de Bree, E.; van Sloothen, G.W.; van Tinteren, H.; Boot, H.; Zoetmulder, F.A. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J. Clin. Oncol. 2003, 21, 3737-3743.
73. Wolff, W.I. Colonoscopy: History and development. Am. J. Gastroenterol. 1989, 84, 1017-1025.
74. Cooper, H.S. Intestinal neoplasm's. In Sternberg's Diagnostic Surgical Pathology, 5th ed.; Mills, S.E., Ed.; Lippincott, Williams & Wilkins: Philadelphia, PA, USA; 2010; pp. 1402-1406.
75. Ruiz-Tovar, J.; Jiménez-Miramón, J.; Valle, A.; Limones, M. Endoscopic resection as unique treatment for early colorectal cancer. Rev. Esp. Enferm. Dig. 2010, 102, 435-441.
76. Bujanda, L.; Cosme, A.; Gil, I.; Arenas-Mirave, J.I. Malignant colorectal polyps. World J. Gastroenterol. 2010, 16, 3103-3111.
77. Kikuchi, R.; Takano, M.; Takagi, K.; Fujimoto, N.; Nozaki, R.; Fujiyoshi, T.; Uchida, Y. Management of early invasive colorectal cancer: Risk of recurrence and clinical guidelines. Dis. Colon Rectum 1995, 38, 1286-1295.
78. Tytherleigh, M.G.; Warren, B.F.; Mortensen, N.J. Management of early rectal cancer. Br. J. Surg. 2008, 95, 409-423.
79. Volk, E.E.; Goldblum, J.R.; Petras, R.E.; Carey, W.D.; Fazio, V.W. Management and outcome of patients with invasive carcinoma arising in colorectal polyps. Gastroenterology 1995, 109, 1801-1807.
80. Kafka, N.J.; Coller, J.A. Endoscopic management of malignant colorectal polyps. Surg. Oncol. Clin. N. Am. 1996, 5, 633-661.
81. Kudo, S.; Kashida, H.; Tamura, T.; Kogure, E.; Imai, Y.; Yamano, H.; Hart, A.R. Colonoscopic diagnosis and management of nonpolypoid early colorectal cancer. World J. Surg. 2000, 24, 1081-1090.
82. Schlemper, R.J.; Riddell, R.H.; Kato, Y.; Borchard, F.; Cooper, H.S.; Dawsey, S.M.; Dixon, M.F.; Fenoglio-Preiser, C.M.; Fléjou, J.F.; Geboes, K., et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000, 47, 251-255.
83. Participants in the Paris Workshop. The Paris endoscopic classification of superficial neoplastic lesions: Esophagus, stomach and colon: November 30 to December 1, 2002. Gastrointest. Endosc. 2003, 58 (Suppl. 6), S3-S43.
84. Cooper, H.S.; Deppisch, L.M.; Gourley, W.K.; Kahn, E.I.; Lev, R.; Manley, P.N.; Pascal, R.R.; Qizilbash, A.H.; Rickert, R.R.; Silverman, J.F. Endoscopically removed malignant colorectal polyps: Clinico-pathologic correlations. Gastroenterology 1995, 108, 1657-1665.
85. Ueno, H.; Mochizuki, H.; Hashiguchi, Y.; Shimazaki, H.; Aida, S.; Hase, K.; Matsukuma, S.; Kanai, T.; Kurihara, H.; Ozawa, K., et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 2004, 127, 385-394.
86. Compton, C.C.; Fielding, L.P.; Burgart, L.J.; Conley, B.; Cooper, H.S.; Hamilton, S.R.; Hammond, M.E.; Henson, D.E.; Hutter, R.V.; Nagle, R.B., et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch. Pathol. Lab. Med. 2000, 124, 979-994.
87. Compton, C. Colorectal carcinoma: Diagnostic, prognostic, and molecular features. Mod. Pathol. 2003, 16, 376-388.
88. Compton, C.; Fenoglio-Preiser, C.M.; Pettigrew, N.; Fielding, L.P. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 2000, 88, 1739-1757.
89. Bentzen, S.M.; Balslev, I.; Pedersen, M.; Teglbjaerg, P.S.; Hanberg-Sørensen, F.; Bone, J.; Jacobsen, N.O.; Sell, A.; Overgaard, J.; Bertelsen, K. et al. Time to loco-regional recurrence after resection of Dukes' B and C colorectal cancer with or without adjuvant postoperative radiotherapy. A multivariate regression analysis. Br. J. Cancer 1992, 65, 102-107.
90. Kakar, S.; Smyrk, T.C. Signet ring cell carcinoma of the colorectum: Correlations between microsatellite instability, clinicopathologic features and survival. Mod. Pathol. 2005, 18, 244-249.
91. Purdie, C.A.; Piris, J. Histopathological grade, mucinous differentiation and DNA ploidy in relation to prognosis in colorectal carcinoma. Histopathology 2000, 36, 121-126.
92. Chew, M.H.; Yeo, S.A.; Ng, Z.P.; Lim, K.H.; Koh, P.K.; Ng, K.H.; Eu, K.W. Critical analysis of mucin and signet ring cell as prognostic factors in an Asian population of 2,764 sporadic colorectal cancers. Int. J. Colorectal Dis. 2010, 25, 1221-1229.
93. Börger, M.E.; Gosens, M.J.; Jeuken, J.W.; van Kempen, L.C.; van de Velde, C.J.; van Krieken, J.H.; Nagtegaal, I.D. Signet ring cell differentiation in mucinous colorectal carcinoma. J. Pathol. 2007, 212, 278-286.
94. McGregor, D.K.; Wu, T-T.; Rashid, A.; Luthra, R.; Hamilton, S.R. Reduced expression of cytokeratin 20 in colorectal cancer with high levels of microsatellite instability. Am. J. Surg. Pathl. 2004, 28, 712-718.
95. Hino, I.T.; Tani, M.; Lucas, P.C.; Caca, K.; Dunn, R.L.; Macri, E.; Loda, M.; Appelman, H.D.; Cho, K.R.; Fearon, E.R. Loss of CDX2 expression and microsatellite instability are prominent features of large cell minimally differentiated carcinomas of the colon. Am. J. Pathol. 2001, 159, 2239-2248.
96. Lanza, G.; Gafà, R.; Matteuzzi, M.; Santini, A. Medullary type poorly differentiated adenocarcinoma of the large bowel: Distinct clinicopatlogical entity characterized by microsatellite instability and improved survival. J. Clin. Oncol. 1999, 17, 2429-2438.
97. Thirunavukarasu, P.; Sathaiah, M.; Singla, S.; Sukumar, S.; Karunamurthy, A.; Pragatheeshwar, K.D.; Lee, K.K.; Zeh, H., 3rd.; Kane, K.M.; Bartlett, D.L. Medullary carcinoma of the large intestine: A population based analysis. Int. J. Oncol. 2010, 37, 901-907.
98. Makinen, M.J. Colorectal serrated adenocrcinoma. Histopathology 2007, 50, 131-150.
99. O'Brien, M.J.; Yang, S.; Mack, C.; Xu, H.; Huang, C.S.; Mulcahy, E.; Amorosino, M.; Farraye, F.A. Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am. J. Surg. Pathol. 2006, 30, 1491-1501.
100. Kambara, T.; Simms, L.A.; Whitehall, V.L.; Spring, K.J.; Wynter, C.V.; Walsh, M.D.; Barker, M.A.; Arnold, S.; McGivern, A.; Matsubara, N., et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 2004, 53, 1137-1144.
101. Harvey, N.T.; Ruszkiewicz, A. Serrated neoplasia of the colorectum. World J. Gastroenterol. 2007, 13, 3792-3798.
102. Jass, J.R. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007, 50, 113-130.
103. Mori, T.; Hirota, T.; Ohashi, Y.; Kodaira, S. Significance of histologic type of primary lesion and metastatic lymph nodes as a prognostic factor in stage III colon cancer. Dis. Colon Rectum 2006, 49, 982-992.
104. Choi, P.W.; Yu, C.S.; Jang, S.J.; Jung, S.H.; Kim, H.C.; Kim, J.C. Risk factors for lymph node metastasis in submucosal invasive colorectal cancer. World J. Surg. 2008, 32, 2089-2094.
105. Law, W.L.; Chu, K.W. Anterior resection for rectal cancer with mesorectal excision: A prospective evaluation of 622 patients. Ann. Surg. 2004, 240, 260-268.
106. Talbot, I.C.; Ritchie, S.; Leighton, M.H.; Hughes, A.O.; Bussey, H.J.; Morson, B.C. The clinical significance of invasion of veins by rectal cancer. Br. J. Surg. 1980, 67, 439-442.
107. Sternberg, A.; Amar, M.; Alfici, R.; Groisman, G. Conclusions from a study of venous invasion in stage IV colorectal adenocarcinoma. J. Clin. Pathol. 2002, 55, 17-21.
108. Puppa, G.; Caneva, A.; Colombari, R. Venous invasion detection in colorectal cancer: Which approach, which technique? J. Clin. Pathol. 2009, 62, 102-103.
109. Liebig, C.; Ayala, G.; Wilks, J.; Berger, D.H.; Albo, D. Perineural invasion in cancer: A review of the literature. Cancer 2009, 115, 3379-3391.
110. Liebig, C.; Ayala, G.; Wilks, J.; Verstovsek, G.; Liu, H.; Agarwal, N.; Berger, D.H.; Albo, D. Perineural invasion is an independent predictor of outcome in colorectal cancer. J. Clin. Oncol. 2009, 27, 5131-5137.
111. Krasna, M.J.; Flancbaumm, L.; Cody, R.P.; Shneibaum, S.; Ben Ari, G. Vascular and neural invasion in colorectal carcinoma. Incidence and prognostic significance. Cancer 1988, 61, 1018-1023.
112. Oñate-Ocaña, L.F.; Montesdeoca, R.; López-Graniel, C.M.; Aiello-Crocifoglio, V.; Mondragón-Sánchez, R.; Cortina-Borja, M.; Herrera-Goepfert, R.; Oros-Ovalle, C.; Gallardo-Rincón, D. Identification of patients with high-risk lymph node-negative colorectal cancer and potential benefit from adjuvant chemotherapy. Jpn. J. Clin. Oncol. 2004, 34, 323-328.
113. Huh, J.W.; Kim, H.R.; Kim, Y.J. Prognostic value of perineural invasion in patients with stage II colorectal cancer. Ann. Surg. Oncol. 2010, 17, 2066-2072.
114. Morodomi, T.; Isomoto, H.; Shirouzu, K.; Kakegawa, K.; Irie, K.; Morimatsu, M. An index for estimating the probability of lymph node metastasis in rectal cancers. Lymph node metastasis and the histopathology of actively invasive regions of cancer. Cancer 1989, 63, 539-543.
115. Hase, K.; Shatney, C.; Johnson, D.; Trollope, M.; Vierra, M. Prognostic value of tumor "budding" in patients with colorectal cancer. Dis. Colon Rectum 1993, 36, 627-635.
116. Imai, T. The growth of human carcinoma: A morphological analysis. Fukuoka Igaku Zasshi 1954, 45, 72-102.
117. Gabbert, H.; Wagner, R.; Moll, R.; Gerharz, C.D. Tumor dedifferentiation: An important step in tumor invasion. Clin. Exp. Metastasis 1985, 3, 257-279.
118. Shinto, E.; Jass, J.R.; Tsuda, H.; Sato, T.; Ueno, H.; Hase, K.; Mochizuki, H.; Matsubara, O. Differential prognostic significance of morphologic invasive markers in colorectal cancer: Tumor budding and cytoplasmic podia. Dis. Colon Rectum 2006, 49, 1422-1430.
119. Prall, F. Tumour budding in colorectal carcinoma. Histopathology 2007, 50, 151-162
120. Okuyama, T.; Oya, M.; Ishikawa, H. Budding as a risk factor for lymph node metastasis in pT1 or pT2 well-differentiated colorectal adenocarcinoma. Dis. Colon Rectum 2002, 45, 628-634.
121. Sy, J.; Fung, C.L.; Dent, O.F.; Chapuis, P.H.; Bokey, L.; Chan, C. Tumor budding and survival after potentially curative resection of node-positive colon cancer. Dis. Colon Rectum 2010, 53, 301-307.
122. Zlobec, I.; Lugli, A. Prognostic and predictive factors in colorectal cancer. J. Clin. Pathol. 2008, 61, 561-569.
123. Zlobec, I.; Molinari, F.; Martin, V.; Mazzucchelli, L.; Saletti, P.; Trezzi, R.; De Dosso, S.; Vlajnic, T.; Frattini, M.; Lugli, A. Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients. World J. Gastroenterol. 2010, 16, 4823-4831.
124. Phillips, S.M.; Banerjea, A.; Feakins, R.; Li, S.R.; Bustin, S.A.; Dorudi, S. Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic. Br. J. Surg. 2004, 91, 469-475.
125. Naito, Y.; Saito, K.; Shiiba, K.; Ohuchi, A.; Saigenji, K.; Nagura, H.; Ohtani, H. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998, 58, 3491-3494.
126. Menon, A.G.; Janssen-van Rhijn, C.M.; Morreau, H.; Putter, H.; Tollenaar, R.A.; van de Velde, C.J.; Fleuren, G.J.; Kuppen, P.J. Immune system and prognosis in colorectal cancer: A detailed immunohistochemical analysis. Lab. Invest. 2004, 84, 493-501.
127. Chiba, T.; Ohtani, H.; Mizoi, T.; Naito, Y.; Sato, E.; Nagura, H.; Ohuchi, A.; Shiiba, K.; Kurokawa, Y.; Satomi, S. Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow- up period in human colorectal carcinoma: Possible association with suppression of micrometastasis. Br. J. Cancer 2004, 91, 1711-1717.
128. Deschoolmeester, V.; Baay, M.; Van Marck, E.; Weyler, J.; Vermeulen, P.; Lardon, F.; Vermorken, JB. Tumor infiltrating lymphocytes: An intriguing player in the survival of colorectal cancer patients. BMC Immunol. 2010, 11, 19.
129. Des Guetz, G.; Uzzan, B.; Nicolas, P.; Cucherat, M.; Morere, J.F.; Benamouzig, R.; Breau, J.L.; Perret, G.Y. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br. J. Cancer 2006, 94, 1823-1832.
130. Svagzdys, S.; Lesauskaite, V.; Pavalkis, D.; Nedzelskiene, I.; Pranys, D.; Tamelis, A. Microvessel density as new prognostic marker after radiotherapy in rectal cancer. BMC Cancer 2009, 9, 95.
131. Ueno, H.; Mochizuki, H.; Hashiguchi, Y.; Ishiguro, M.; Miyoshi, M.; Kajiwara, Y.; Sato, T.; Shimazaki, H.; Hase, K. Extramural cancer deposits without nodal structure in colorectal cancer, optimal categorization for prognostic staging. Am. J. Clin. Pathol. 2007, 127, 287-294.
132. Nagtegaal, I.D.; Quirke, P. Colorectal tumour deposits in the mesorectum and pericolon: A critical review. Histopathology 2007, 51, 141-149.
133. Puppa, G.; Maisonneuve, P.; Sonzogni, A.; Masullo, M.; Capelli, P.; Chilosi, M.; Menestrina, F.; Viale, G.; Pelosi, G. Pathological assessment of pericolonic tumor deposits in advanced colonic carcinoma: Relevance to prognosis and tumor staging. Mod. Pathol. 2007, 20, 843-855.
134. Quer, E.A.; Dahlin, D.C.; Mayo, C.W. Retrograde intramural spread of carcinoma of the rectum and rectosigmoid: A microscopic study. Surg. Gynecol. Obstet. 1953, 96, 24-30.
135. Grinnell, R.S. Distal intramural spread of carcinoma of the rectum and rectosigmoid. Surg. Gynecol. Obstet. 1954, 99, 421-430.
136. Pollett, W.G.; Nicholls, R.J. The relationship between the extent of distal clearance and survival and local recurrence rates after curative anterior resection for carcinoma of the rectum. Ann. Surg. 1983, 198, 159-163.
137. Williams, N.S.; Dixon, M.F.; Johnston, D. Reappraisal of the 5 centimetre rule of distal excision for carcinoma of the rectum, a study of distal intramural spread and of patients' survival. Br. J. Surg. 1983, 70, 150-154.
138. Marks, G.; Mohiuddin, M.; Masoni, L. The reality of radical sphincter preservation surgery for cancer of the distal 3 cm of rectum following high-dose radiation. Int. J. Radiat. Oncol. Biol. Phys. 1993, 27, 779-83.
139. Park, I.J.; Kim, J.C. Adequate length of the distal resection margin in rectal cancer, from the oncological point of view. J. Gastrointest. Surg. 2010, 14, 1331-1337.
140. Pricolo, V.E.; Abodeely, A.; Resnick, M. Distal margins in radical resections for rectal cancer after chemoradiation therapy: How short is long enough? Dig. Surg. 2010, 27, 185-189.
141. Bannon, J.P.; Marks, G.J.; Mohiuddin, M.; Rakinic, J.; Jian, N.Z.; Nagle, D. Radical and local excisional methods of sphincter-sparing surgery after high-dose radiation for cancer of the distal 3 cm of the rectum. Ann. Surg. Oncol. 1995, 2, 221-227.
142. Vorobiev, G.I.; Odaryuk, T.S.; Tsarkov, P.V.; Talalakin, A.I.; Rybakov, E.G. Resection of the rectum and total excision of the internal anal sphincter with smooth muscle plasty and colonic pouch for treatment of ultralow rectal carcinoma. Br. J. Surg. 2004, 91, 1506-1512.
143. Zhou, J.N.; Wang, D.Z.; Huang, X.E.; Xu, F.P.; Shang, J.Q.; Gu, RM. Transabdominal transanal resection of distal rectal cancer after high dose preoperative radiotherapy: A Chinese experience in preserving sphincter function. Isr. Med. Assoc. J. 2006, 8, 675-678.
144. Tilney, H.S.; Tekkis, P.P. Extending the horizons of restorative rectal surgery: Intersphincteric resection for low rectal cancer. Colorectal Dis. 2008, 10, 3-15.; discussion 15-16.
145. Akasu, T.; Takawa, M.; Yamamoto, S.; Ishiguro, S.; Yamaguchi, T.; Fujita, S.; Moriya, Y.; Nakanishi, Y. Intersphincteric resection for very low rectal adenocarcinoma: Univariate and multivariate analyses of risk factors for recurrence. Ann. Surg. Oncol. 2008, 15, 2668-2676.
146. Weiser, M.R.; Quah, H.M.; Shia, J.; Guillem, J.G.; Paty, P.B.; Temple, L.K.; Goodman, K.A.; Minsky, B.D.; Wong, W.D. Sphincter preservation in low rectal cancer is facilitated by preoperative chemoradiation and intersphincteric dissection. Ann. Surg. 2009, 249, 236-242.
147. Marks, J.; Mizrahi, B.; Dalane, S.; Nweze, I.; Marks, G. Laparoscopic transanal abdominal transanal resection with sphincter preservation for rectal cancer in the distal 3 cm of the rectum after neoadjuvant therapy. Surg. Endosc. 2010, 24, 2700-277.
148. Nash, G.M.; Weiss, A.; Dasgupta, R.; Gonen, M.; Guillem, J.G.; Wong, W.D. Close distal margin and rectal cancer recurrence after sphincter-preserving rectal resection. Dis. Colon Rectum 2010, 53, 1365-1373.
149. Pullyblank, A.M.; Kirwan, C.; Rigby, H.S.; Dixon, A.R. Is routine histological reporting of doughnuts justified after anterior resection for colorectal cancer? Colorectal Dis. 2001, 3, 198-200.
150. Speake, W.J.; Abercrombie, J.F. Should "doughnut' histology be routinely performed following anterior resection for rectal cancer? Ann. R. Coll. Surg. Engl. 2003, 85, 26-27.
151. Heald, R.J.; Ryall, R.D. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986, 1, 1479-1482.
152. Quirke, P.; Durdey, P.; Dixon, M.F.; Williams, N.S. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet 1986, 2, 996-999.
153. Quirke, P.; Dixon, M.F. The prediction of local recurrence in rectal adenocarcinoma by histopathological examination. Int. J. Colorectal Dis. 1988, 3, 127-131.
154. Nagtegaal, I.D.; Quirke, P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J. Clin. Oncol. 2008, 26, 303-312.
155. Bateman, A.C.; Carr, N.J.; Warren, B.F. The retroperitoneal surface in distal caecal and proximal ascending colon carcinoma: The Cinderella surgical margin? J. Clin. Pathol. 2005, 58, 426-428.
156. Scott, N.; Jamali, A.; Verbeke, C.; Ambrose, N.S.; Botterill, I.D.; Jayne, D.G. Retroperitoneal margin involvement by adenocarcinoma of the caecum and ascending colon: What does it mean? Colorectal Dis. 2008, 10, 289-293.
157. Nagtegaal, I.D.; van de Velde, C.J.; Marijnen, C.A.; van Krieken, J.H.; Quirke, P.; Dutch Colorectal Cancer Group.; Pathology Review Committee. Low rectal cancer: A call for a change of approach in abdominoperineal resection. J. Clin. Oncol. 2005, 23, 9257-9264.
158. Marr, R.; Birbeck, K.; Garvican, J.; Macklin, C.P.; Tiffin, N.J.; Parsons, W.J.; Dixon, M.F.; Mapstone, N.P.; Sebag-Montefiore, D.; Scott, N., et al. The modern abdominoperineal excision: The next challenge after total mesorectal excision. Ann. Surg. 2005, 242, 74-82.
159. Morris, E.; Quirke, P.; Thomas, J.D.; Fairley, L.; Cottier, B.; Forman, D. Unacceptable variation in abdominoperineal excision rates for rectal cancer: Time to intervene? Gut 2008, 57, 1690-1697.
160. Shihab, O.C.; Brown, G.; Daniels, I.R.; Heald, R.J.; Quirke, P.; Moran, B.J. Patients with low rectal cancer treated by abdominoperineal excision have worse tumors and higher involved margin rates compared with patients treated by anterior resection. Dis. Colon Rectum 2010, 53, 53-56.
161. Quirke, P.; Morris, E. Reporting colorectal cancer. Histopathology 2007, 50, 103-112.
162. West, N.P.; Sutton, K.M.; Ingeholm, P.; Hagemann-Madsen, R.H.; Hohenberger, W.; Quirke, P. Improving the quality of colon cancer surgery through a surgical education program. Dis. Colon Rectum 2010, 53, 1594-1603.
163. West, N.P.; Finan, P.J.; Anderin, C.; Lindholm, J.; Holm, T.; Quirke, P. Evidence of the oncologic superiority of cylindrical abdominoperineal excision for low rectal cancer. J. Clin. Oncol. 2008, 26, 3517-3522.
164. Davies, M.; Harris, D.; Hirst, G.; Beynon, R.; Morgan, A.R.; Carr, N.D.; Beynon, J. Local recurrence after abdomino-perineal resection. Colorectal Dis. 2009, 11, 39-43.
165. Andreoni, B.; Chiappa, A.; Bertani, E.; Bellomi, M.; Orecchia, R.; Zampino, M.; Fazio, N.; Venturino, M.; Orsi, F.; Sonzogni, A., et al. Surgical outcomes for colon and rectal cancer over a decade: Results from a consecutive monocentric experience in 902 unselected patients. World J. Surg. Oncol. 2007, 5, 73.
166. Croner, R.S.; Merkel, S.; Papadopoulos, T.; Schellerer, V.; Hohenberger, W.; Goehl, J. Multivisceral resection for colon carcinoma. Dis. Colon Rectum 2009, 52, 1381-1386.
167. Zoucas, E.; Frederiksen, S.; Lydrup, M.L.; Månsson, W.; Gustafson, P.; Alberius, P. Pelvic exenteration for advanced and recurrent malignancy. World J. Surg. 2010, 34, 2177-2184.
168. Liang, Y.; Li, G.; Chen, P.; Yu, J. Laparoscopic versus open colorectal resection for cancer: A meta-analysis of results of randomized controlled trials on recurrence. Eur. J. Surg. Oncol. 2008, 34, 1217-1224.
169. Kuhry, E.; Schwenk, W.; Gaupset, R.; Romild, U.; Bonjer, J. Long-term outcome of laparoscopic surgery for colorectal cancer: A cochrane systematic review of randomised controlled trials. Cancer Treat. Rev. 2008, 34, 498-504.
170. Leroy, J.; Marescaux, J. Double plastic wound protection for specimen extraction in colorectal surgery. Available online: http://www.websurg.com/ref/Double_plastic_wound_protection_for_specimen_extraction_in_colorectal_surgery-vd01en2589.htm/ (accessed 2 June 2011).
171. Richman, S.D.; Hutchins, G.G.; Seymour, M.T.; Quirke, P. What can the molecular pathologist offer for optimal decision making? Ann. Oncol. 2010, 21 (Suppl. 7), 7123-7129.
172. Ghaleb, A.M.; Yang, V.W. The pathobiology of Kru ppel-like factors in colorectal cancer. Curr. Colorectal Cancer Rep. 2008, 4, 59-64.
173. Wood, L.D.; Parsons, D.W.; Jones, S.; Lin, J.; Sjöblom, T.; Leary, R.J.; Shen, D.; Boca, S.M.; Barber, T.; Ptak, J., et al. The genomic landscapes of human breast and colorectal cancers. Science 2007, 318, 1108-1113.
174. Kerr, D.J.; Midgley, R. Defective mismatch repair in colon cancer, a prognostic or predictive biomarker? J. Clin. Oncol. 2010, 28, 3210-322.
175. Vogelstein, B.; Fearon, E.R.; Hamilton, S.R.; Kern, S.E.; Preisinger, A.C.; Leppert, M.; Nakamura, Y.; White, R.; Smits, A.M.; Bos, J.L. Genetic alterations during colorectal tumour development. N. Engl. J. Med. 1988, 319, 525-532.
176. de la Chapelle, A. Microsatellite Instability. N. Engl. J. Med. 2003, 349, 17.
177. Boland, C.R.; Thibodeau, S.N.; Hamilton, S.R.; Sidransky, D.; Eshleman, J.R.; Burt, R.W.; Meltzer, S.J.; Rodriguez-Bigas, M.A.; Fodde, R.; Ranzani, G.N., et al. National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998, 58, 5248-5257.
178. Aaltonen, L.A.; Peltomäki, P.; Leach, F.S.; Sistonen, P.; Pylkkänen, L.; Mecklin, J.P.; Järvinen, H.; Powell, S.M.; Jen, J.; Hamilton, S.R., et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993, 260, 812-816.
179. Kinzler, K.W.; Vogelstein, B. Lessons from hereditary colorectal cancer. Cell 1996, 87, 159-170.
180. Lawes, D.A.; SenGupta, S.; Boulos, P.B.; The clinical importance and prognostic implications of microsatellite instability in sporadic cancer. Eur. J. Surg. Oncol. 2003, 29, 201.
181. Wright, C.I.; Stewart, I.D. Histopathology and mismatch repair status of 458 consecutive colorectal carcinomas. Am. J. Surg. Pathol. 2003, 27, 1393-1406.
182. Smyrk, T.C.; Watson, P.; Kaul, K.; Lynch, H.T. Tumour infiltrating lymphocytes are a marker for microsatellite instability in colorectal cancer. Cancer 2001, 91, 2417-2422.
183. Jenkins, M.A.; Hayashi, S.; O'Shea, A.M.; Burgart, L.J.; Smyrk, T.C.; Shimizu, D.; Waring, P.M.; Ruszkiewicz, A.R.; Pollett, A.F.; Redston, M., et al. Pathology features in Besthesda guidelines predict colorectal cancer microsatellite instability: A population based study. Gastroentrology 2007, 133, 48-56.
184. Wheeler, J.M.; Boder, W.F.; McMortensen, N.J. DNA mismatch repair genes in colorectal cancer. Gut 2000, 47, 148-153.
185. Kane, M.F.; Loda, M.; Gaida, G.M.; Lipman, J.; Mishra, R.; Goldman, H.; Jessup, J.M.; Kolodner, R. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 1997, 57, 808-811.
186. Cunningham, J.M.; Christensen, E.R.; Tester, D.J.; Kim, C.Y.; Roche, P.C.; Burgart, L.J.; Thibodeau, S.N. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res. 1998, 58, 3455-3460.
187. Toyota, M.; Ahuja, N.; Ohe-Toyota, M.; Herman, J.G.; baylin, S.B.; Issa, J-P. CpG island methylator pheno- type in colorectal cancer. Proc. Natl. Acad. Sci. USA 1999, 96, 8681-8686.
188. Hendriks, Y.M.; de Jong, A.E.; Morreau, H.; Tops, C.M.; Vasen, H.F.; Wijnen, J.T.; Breuning, M.H.; Bröcker-Vriends, A.H. Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): A guide for clinicians. CA Cancer J. Clin. 2006, 56, 213-225.
189. Ng, K.; Schrag D. Microsatellite instability and adjuvant fluorouracil chemotherapy, a mismatch? J. Clin. Oncol. 2010, 28, 3207-3210.
190. Umar, A.; Boland, C.R.; Terdiman, J.P.; Syngal, S.; de la Chapelle, A.; Rüschoff, J.; Fishel, R.; Lindor, N.M.; Burgart, L.J.; Hamelin, R., et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J. Natl. Cancer Inst. 2004, 96, 261-268.
191. Lanza, G.; Gafa, R.; Santini A.; Maestri, I.; Guerzoni, L.; Cavazzini, L.; Immunohistochemical tests for MLH-1 and MSH-2 expression predicts clinical outcome in stage II and stage III colorectal cancer patients. J. Clin. Oncol. 2006, 24, 2359-2367.
192. Elsaleh, H.; Iacopetta, B. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma. Clin. Colorectal Cancer 2001, 1, 104-109.
193. Ribic, C.M.; Sargent, D.J.; Moore, M.J.; Thibodeau, S.N.; French, A.J.; Goldberg, R.M.; Hamilton, S.R.; Laurent-Puig, P.; Gryfe, R.; Shepherd, L.E., et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 2003, 349, 247-257.
194. Popat, S.; Hubner, R.; Houlston, R.S. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol. 2005, 23, 609-618.
195. Kim, G.P.; Colangelo, L.H.; Wieand, H.S.; Paik, S.; Kirsch, I.R.; Wolmark, N.; Allegra, C.J. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer, a national cancer institute-national surgical adjuvant breast and bowel project collaborative study. J. Clin. Oncol. 2007, 25, 767-772.
196. Sinicrope, F.A.; Sargent, D.J. Clinical implications of microsatellite instability in sporadic colon cancers. Curr. Opin. Oncol. 2009, 21, 369-373.
197. Sargent, D.J.; Marsoni, S.; Monges, G.; Thibodeau, S.N.; Labianca, R.; Hamilton, S.R.; French, A.J.; Kabat, B.; Foster, N.R.; Torri, V., et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J. Clin. Oncol. 2010, 28, 3219-3226.
198. Samowitz, W.S.; Sweeney, C.; Herrick, J.; Albertsen, H.; Levin, T.R.; Murtaugh, M.A.; Wolff, R.K.; Slattery, M.L. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 2005, 65, 6063-6069.
199. Jover, R.; Zapater, P.; Castells, A.; Llor, X.; Andreu, M.; Cubiella, J.; Balaguer, F.; Sempere, L.; Xicola, R.M.; Bujanda, L. et al. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur. J. Cancer 2009, 45, 365-373.
200. Carethers, J.M.; Chauhan, D.P.; Fink, D.; Nebel, S.; Bresalier, R.S.; Howel, S.B.; Boland, C.R. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroentrology 1999, 117, 123-131.
201. French, A.J.; Sargent, D.J.; Burgart, L.J.; Foster N.R.; Kabat, B.F.; Goldberg, R.; Shepherd, L.; Windschitl, H.E.; Thibodeau, S.N. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin. Cancer Res. 2008, 14, 3408-3415.
202. Peyssonnaux, C.; Eychène, A. The Raf/MEK/ERK pathway: New concepts of activation. Biol. Cell 2001, 93, 53-62.
203. Davies, H.; Bignell, GR.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, MJ.; Bottomley, W., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417, 949-954.
204. Wellbrock, C.; Karasarides, M.; Marais, R. The RAF proteins take centre stage. Nat. Rev. Mol. Cell Biol. 2004, 5, 875-885.
205. Garnett, M.J.; Rana, S.; Paterson, H.; Barford, D.; Marais, R. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol. Cell 2005, 20, 963-969.
206. Richman, S.D.; Seymour, M.T.; Chambers, P.; Elliott, F.; Daly, C.L.; Meade, A.M.; Taylor, G.; Barrett, J.H.; Quirke, P. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan, results from the MRC FOCUS trial. J. Clin. Oncol. 2009, 27, 5931-5937.
207. Vogelstein, B.; Kinzler, K.W. Cancer genes and the pathways they control. Nat. Med. 2004, 10, 789-799.
208. Rajagopalan, H.; Bardelli, A.; Lengauer, C.; Kinzler, KW.; Vogelstein, B.; Velculescu, VE. Tumorigenesis, RAF/RAS oncogenes and mismatch-repair status. Nature 2002, 418, 934.
209. Fransén, K.; Klintenäs, M.; Osterström, A.; Dimberg, J.; Monstein, HJ.; Söderkvist, P. Mutation analysis of the BRAF.; ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 2004, 25, 527-533.
210. Worthley, D.L.; Whitehall, V.L.; Spring, K.J.; Leggett, B.A. Colorectal carcinogenesis: Road maps to cancer. World J. Gastroenterol. 2007, 13, 3784-3791.
211. Yarden, Y.; Sliwkowski, M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001, 2, 127-137.
212. Scaltriti, M.; Baselga, J. The epidermal growth factor receptor pathway: A model for targeted therapy. Clin. Cancer Res. 2006, 12, 5268-5272.
213. Tabernero, J.; Van Cutsem, E.; Diaz-Rubio, E.; Cervantes, A.; Humblet, Y.; André, T.; Van Laethem, J-L.; Soulie, P. Casado, E.; Verslype, C., et al. Phase II trial of cetuximab in combination with fluorouracil.; leucovorin.; and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 2007, 25, 5225-5232.
214. Di Nicolantonio, F.; Martini, M.; Molinari, F.; Sartore-Bianchi, A.; Arena, S.; Saletti, P.; De Dosso, S.; Mazzucchelli, L.; Frattini, M.; Siena, S., et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 2008, 26, 5705-5712.
215. Karapetis, C.S.; Khambata-Ford, S.; Jonker, D.J.; O'Callaghan, C.J.; Tu D.; Tebbutt, N.C.; Simes, R.J.; Chalchal, H.; Shapiro, J.D.; Robitaille, S., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 2008, 359, 1757-1765.
216. Souglakos, J.; Philips, J.; Wang, R.; Marwah, S.; Silver, M.; Tzardi, M.; Silver, J.; Ogino, S.; Hooshmand, S.; Kwak, E., et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. J. Cancer 2009, 101, 465-472.
217. Amado, R.G.; Wolf, M.; Peeters, M.; Van Cutsem, E.; Siena, S.; Freeman, D.J.; Juan, T.; Sikorski, R.; Suggs, S.; Radinsky, R., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26, 1626-1634.
218. De Roock, W.; Piessevaux, H.; De Schutter, J.; Janssens, M.; De Hertogh, G.; Personeni, N.; Biesmans, B.; Van Laethem, J.L.; Peeters, M.; Humblet, Y., et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann. Oncol. 2008, 19, 508-515.
219. Tejpar, S.; Bertagnolli, M.; Bosman, F.; Lenz, H.J.; Garraway, L.; Waldman, F.; Warren, R.; Bild, A.; Collins-Brennan, D.; Hahn, H., et al. A. Prognostic and predictive biomarkers in resected colon cancer, current status and future perspectives for integrating genomics into biomarker discovery. Oncologist 2010, 15, 390-404.
220. Oliveira, C.; Velho, S.; Moutinho, C.; Ferreira, A.; Preto, A.; Domingo, E.; Capelinha, A.F.; Duval A.; Hamelin, R.; Machado, J.C., et al. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene 2007, 26, 158-163.
221. Cejas, P.; López-Gómez, M.; Aguayo, C.; Madero, R.; de Castro Carpeño, J.; Belda-Iniesta, C.; Barriuso, J.; Moreno García, V.; Larrauri, J.; López, R., et al. KRAS mutations in primary colorectal cancer tumours and related metastases. A potential role in prediction of lung metastases. PLoS One 2009, 4, e8199.
222. Andreyev, H.J.; Norman, A.R.; Cunningham, D.; Oates, J.; Dix, B.R.; Iacopetta, B.J.; Young, J.; Walsh, T; Ward, R.; Hawkins, N., et al. Kirsten ras mutations in patients with colorectal cancer: The "RASCAL II' study. Br. J. Cancer 2001, 85, 692-696.
223. Roth, A.D.; Tejpar, S.; Delorenzi, M.; Yan, P.; Fiocca, R.; Klingbiel, D.; Dietrich, D.; Biesmans, B.; Bodoky, G.; Barone, C., et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer, results of the translational study on the PETACC-3.; EORTC 40993.; SAKK 60-00 trial. J. Clin. Oncol. 2010, 28, 466-474.
224. Ogino, S.; Meyerhardt, J.A.; Irahara, N.; Niedzwiecki, D.; Hollis, D.; Saltz, L.B.; Mayer, R.J.; Schaefer, P.; Whittom, R.; Hantel, A., et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin. Cancer Res. 2009, 15, 7322-7329.
225. Fariña-Sarasqueta, A.; van Lijnschoten, G.; Moerland, E.; Creemers, G.J.; Lemmens, V.E.; Rutten, H.J.; van den Brule, A.J. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann. Oncol. 2010, 21, 2396-2402.
226. Bardelli, A.; Siena, S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J. Clin. Oncol. 2010, 28, 1254-1261.
227. Sartore-Bianchi, A.; Di Nicolantonio, F.; Nichelatti, M.; Molinari, F.; De Dosso, S.; Saletti, P.; Martini, M.; Cipani, T.; Marrapese, G.; Mazzucchelli, L., et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 2009, 4, e7287.
228. Herman, J.G.; Baylin, S.B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 2003, 349, 2042-54.
229. Kondo, Y.; Issa, J.P. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev. 2004, 23, 29-39.
230. Van Rijnsoever, M.; Grieu, F.; Elsaleh, H.; Joseph, D.; Iacopetta, B. Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut 2002, 51, 797-802.
231. Chirieac, L.R.; Shen, L.; Catalano, P.J.; Issa, J.P.; Hamilton, S.R. Phenotype of microsatellite-stable colorectal carcinomas with CpG island methylation. Am. J. Surg. Pathol. 2005, 29, 429-436.
232. Ogino, S.; Meyerhardt, J.A.; Kawasaki, T.; Clark, J.W.; Ryan, D.P.; Kulke, M.H.; Enzinger, P.C.; Wolpin, B.M.; Loda, M.; Fuchs, C.S. CpG island methylation. Response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch. 2007, 450, 529-537.
233. Van Rijnsoever, M.; Elsaleh, H.; Joseph, D.; McCaul, K.; Iacopetta, B. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin. Cancer Res. 2003, 9, 2898-903.
234. Ogino, S.; Nosho, K.; Kirkner, G.J.; Kawasaki, T.; Meyerhardt, J.A.; Loda, M.; Giovannucci, E.L.; Fuchs, C.S. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009, 58, 90-96.
235. Barault, L.; Charon-Barra, C.; Jooste, V.; de la Vega, M.F.; Martin, L.; Roignot, P.; Rat, P.; Bouvier, A.M.; Laurent-Puig, P.; Faivre, J., et al. Hypermethylator phenotype in sporadic colon cancer: Study on a population-based series of 582 cases. Cancer Res. 2008, 68, 8541-8546.
236. Shen, L.; Catalano, P.J.; Benson, A.B., 3rd.; O'Dwyer, P.; Hamilton, S.R.; Issa, J.P. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin. Cancer Res. 2007, 13, 6093-6098.
237. Lurje, G.; Zhang, W.; Yang, D.; Groshen, S.; Hendifar, A.E.; Husain, H.; Nagashima, F.; Chang, H.M.; Fazzone, W.; Ladner, R.D., et al. Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Pharmacogenet Genomics. Gut 2008, 18, 161-168.
238. Villafranca, E.; Okruzhnov, Y.; Dominguez, M.A.; García-Foncillas, J.; Azinovic, I.; Martínez, E.; Illarramendi, J.J.; Arias, F.; Martínez Monge, R.; Salgado, E., et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J. Clin. Oncol. 2001, 19, 1779-1786.
239. Tan, B.R.; Thomas, F.; Myerson, R.J.; Zehnbauer, B.; Trinkaus, K.; Malyapa, R.S.; Mutch, M.G.; Abbey, E.E.; Alyasiry, A.; Fleshman, J.W., et al. Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma. J. Clin. Oncol. 2011, 29, 875-883.
240. Ogino, S.; Nosho, K.; Irahara, N.; Shima, K.; Baba, Y.; Kirkner, G.J.; Meyerhardt, J.A.; Fuchs, C.S. Prognostic significance and molecular associations of 18q loss of heterozygosity: A cohort study of microsatellite stable colorectal cancers. J. Clin. Oncol. 2009, 27, 4591-4598.
241. Pritchard, C.C.; Grady, W.M. Colorectal cancer molecular biology moves into clinical practice. Gut 2011, 60, 116-129.
242. Watanabe, T.; Wu, T.T.; Catalano, P.J.; Ueki, T.; Satriano, R.; Haller, D.G.; Benson, A.B., 3rd; Hamilton, S.R. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 2001, 344, 1196-1206.
243. Popat, S.; Houlston, R.S. A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur. J. Cancer 2005, 41, 2060-2070.
244. Li, M.; Li, J.Y.; Zhao, A.L.; He, J.S.; Zhou, L.X.; Li, Y.A.; Gu, J. Comparison of carcinoembryonic antigen prognostic value in serum and tumour tissue of patients with colorectal cancer. Colorectal Dis. 2009, 11, 276-281.